A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 90
- 试验地点
- 13
- 主要终点
- Evaluation of Objective Response Rate (ORR)
研究概览
简要总结
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP inhibitors.
详细描述
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with Cap vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP inhibitors. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who have been treated with chemotherapy in the metastatic setting.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged ≥18 years at Screening
- •Diagnosis of histologically confirmed breast cancer that is unresectable. The following subsets of breast cancer are included:
- •Patients with triple-negative breast cancer, advanced or metastatic
- •Patients with hormone receptor (HR) positive, ER positive, HER2 negative advanced or metastatic breast cancer
- •Has measurable disease in accordance with RECIST 1.1 obtained by imaging within 28 days prior to C1D1
- •Other therapies are not indicated (eg, resistant or intolerant to taxanes and/or an anthracycline-containing regimen) for treatment of advanced or metastatic breast cancer
- •Has a life expectance of at least 24 weeks
- •Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1 at screening
- •Has adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements conducted within 7 days before C1D1 (Note: labs will also be repeated pre-dose on C1D1 to confirm eligibility): a. Hemoglobin ≥9 g/dL (≥90 g/L) b. Adequate renal function by estimated glomerular filtration rate (eGFR) defined as a creatinine clearance >50 mL/min (>0.84 mL/s) (Cockcroft-Gault equation) and normalized to body surface area c. Peripheral absolute neutrophil count (ANC) of ≥1.5×109/L d. Platelet count of ≥100×109/L without growth factor/transfusion e. Total bilirubin <1.5× upper limit of normal (ULN); or ≤3×ULN if the patient has Gilbert's disease f. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <2.5×ULN, with liver metastasis <5×ULN g. International normalized ratio (INR) <1.5 and prothrombin time (PT) ≤1.5×ULN, unless both of the following conditions are met: i. Patient is receiving anticoagulant therapy, and ii. PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulant h. Activated partial thromboplastin time (aPTT) ≤1.5×ULN, unless both of the following conditions are met: i. Patient is receiving anticoagulant therapy, and ii. PT or PTT is within therapeutic range of intended use of anticoagulants
排除标准
- •Received any line of treatment for advanced or metastatic breast cancer within 21 days or 5 half-lives (whichever is longer) prior to randomization
- •Currently receiving any hormone replacement therapy, unless discontinued within 21 days prior to randomization
- •Received IV 5-FU or oral 5-FU analog in the 4 weeks prior to C1D1
- •Received DPD inhibitor within 4 weeks prior to C1D1
- •Has homozygous or compound heterozygous DPYD variants that result in complete or near-complete absence of DPD activity
- •Has history or presence of clinically significant abnormal 12-lead electrocardiogram (ECG) results, in the Medical Monitor or Investigator's opinion
- •Has prolonged QTc (with Fridericia's correction) of >480 msec performed at Screening
- •Has a history of prolonged QTc interval, ventricular tachycardia/fibrillation or significant ventricular arrhythmia, or Torsades de Pointes, or a history of ventricular ablation for arrhythmia
- •Has congenital long QT syndrome or a family history of long QT syndrome
- •Has other clinically significant cardiac disease including, but not limited to, myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery ≤12 months prior to randomization, congestive heart failure
- •Class II per the New York Heart Association, or history of myocarditis
- •Is pregnant or breastfeeding
研究组 & 干预措施
Capecitabine 2000 mg/m2
Standard capecitabine dose at 1000 mg/m2 BID
干预措施: Capecitabine (Drug)
PCS6422 40 mg + Capecitabine 300 mg
Fixed single dose of PCS6422 administered with Capecitabine 150 mg BID over 7 days
干预措施: PCS6422 and capecitabine (Drug)
PCS6422 40 mg + Capecitabine 450 mg or 150 mg
Fixed single dose of PCS6422 administered with Capecitabine 225 mg or 75 mg BID over 7 days
干预措施: PCS6422 and capecitabine (Drug)
结局指标
主要结局
Evaluation of Objective Response Rate (ORR)
时间窗: Up to 24 weeks post End of Treatment (EoT)
The proportion of patients who achieved a confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Number of patients with adverse events (AEs)
时间窗: During treatment, an average of 8 months
Frequency, duration, and severity of AEs across treatment groups
次要结局
- Evaluation of Disease Control Rate (DCR)(Up to 24 weeks post End of Treatment (EoT))
- Evaluation of Duration of Response (DOR)(Up to 24 weeks post End of Treatment (EoT))
- Evaluation of Time to Response (TTR)(Every 12 weeks during treatment)
- Evaluation of Progression Free Survival (PFS)(Up to 24 weeks post End of Treatment (EoT))